Literature DB >> 22493083

Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.

Shilpa Sanapala1, Jieh-Juen Yu, Ashlesh K Murthy, Weidang Li, M Neal Guentzel, James P Chambers, Karl E Klose, Bernard P Arulanandam.   

Abstract

A licensed vaccine against Francisella tularensis is currently not available. Two Francisella tularensis subsp. novicida (herein referred to by its earlier name, Francisella novicida) attenuated strains, the ΔiglB and ΔfopC strains, have previously been evaluated as potential vaccine candidates against pneumonic tularemia in experimental animals. F. novicida ΔiglB, a Francisella pathogenicity island (FPI) mutant, is deficient in phagosomal escape and intracellular growth, whereas F. novicida ΔfopC, lacking the outer membrane lipoprotein FopC, which is required for evasion of gamma interferon (IFN-γ)-mediated signaling, is able to escape and replicate in the cytosol. To dissect the difference in protective immune mechanisms conferred by these two vaccine strains, we examined the efficacy of the F. novicida ΔiglB and ΔfopC mutants against pulmonary live-vaccine-strain (LVS) challenge and found that both strains provided comparable protection in wild-type, major histocompatibility complex class I (MHC I) knockout, and MHC II knockout mice. However, F. novicida ΔfopC-vaccinated but not F. novicida ΔiglB-vaccinated perforin-deficient mice were more susceptible and exhibited greater bacterial burdens than similarly vaccinated wild-type mice. Moreover, perforin produced by natural killer (NK) cells and release of granzyme contributed to inhibition of LVS replication within macrophages. This NK cell-mediated LVS inhibition was enhanced with anti-F. novicida ΔfopC immune serum, suggesting antibody-dependent cell-mediated cytotoxicity (ADCC) in F. novicida ΔfopC-mediated protection. Overall, this study provides additional immunological insight into the basis for protection conferred by live attenuated F. novicida strains with different phenotypes and supports further investigation of this organism as a vaccine platform for tularemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493083      PMCID: PMC3370591          DOI: 10.1128/IAI.00036-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  72 in total

Review 1.  Recent advances in antigen processing and presentation.

Authors:  Peter E Jensen
Journal:  Nat Immunol       Date:  2007-10       Impact factor: 25.606

2.  Evolution, benefits, and shortcomings of vaccine management.

Authors:  Jonathan A McCullers
Journal:  J Manag Care Pharm       Date:  2007-09

3.  Construction of targeted insertion mutations in Francisella tularensis subsp. novicida.

Authors:  Jirong Liu; Xhavit Zogaj; Jeffrey R Barker; Karl E Klose
Journal:  Biotechniques       Date:  2007-10       Impact factor: 1.993

4.  Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant.

Authors:  G Boltz-Nitulescu; C Wiltschke; C Holzinger; A Fellinger; O Scheiner; A Gessl; O Förster
Journal:  J Leukoc Biol       Date:  1987-01       Impact factor: 4.962

5.  Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules.

Authors:  E R Podack; J D Young; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection.

Authors:  Heather J Powell; Yu Cong; Jieh-Juen Yu; M Neal Guentzel; Michael T Berton; Karl E Klose; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Immunol Cell Biol       Date:  2008-04-22       Impact factor: 5.126

7.  Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns.

Authors:  Chris A Mares; Sandra S Ojeda; Elizabeth G Morris; Qun Li; Judy M Teale
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

8.  A conserved alpha-helix essential for a type VI secretion-like system of Francisella tularensis.

Authors:  Jeanette E Bröms; Moa Lavander; Anders Sjöstedt
Journal:  J Bacteriol       Date:  2009-02-06       Impact factor: 3.490

9.  NK cells and gamma interferon coordinate the formation and function of hepatic granulomas in mice infected with the Francisella tularensis live vaccine strain.

Authors:  Sirosh M Bokhari; Kee-Jun Kim; David M Pinson; Joyce Slusser; Hung-Wen Yeh; Michael J Parmely
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

10.  Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains.

Authors:  Laurence Rohmer; Christine Fong; Simone Abmayr; Michael Wasnick; Theodore J Larson Freeman; Matthew Radey; Tina Guina; Kerstin Svensson; Hillary S Hayden; Michael Jacobs; Larry A Gallagher; Colin Manoil; Robert K Ernst; Becky Drees; Danielle Buckley; Eric Haugen; Donald Bovee; Yang Zhou; Jean Chang; Ruth Levy; Regina Lim; Will Gillett; Don Guenthener; Allison Kang; Scott A Shaffer; Greg Taylor; Jinzhi Chen; Byron Gallis; David A D'Argenio; Mats Forsman; Maynard V Olson; David R Goodlett; Rajinder Kaul; Samuel I Miller; Mitchell J Brittnacher
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  6 in total

1.  Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response.

Authors:  Manish Mahawar; Maninjay K Atianand; Rachel J Dotson; Vanessa Mora; Seham M Rabadi; Dennis W Metzger; Jason F Huntley; Jonathan A Harton; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

2.  Role of NK cells in host defense against pulmonary type A Francisella tularensis infection.

Authors:  Deanna M Schmitt; Dawn M O'Dee; Matthew J Brown; Joseph Horzempa; Brian C Russo; Penelope A Morel; Gerard J Nau
Journal:  Microbes Infect       Date:  2012-12-01       Impact factor: 2.700

3.  Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB.

Authors:  Aimee L Cunningham; Kim Minh Dang; Jieh-Juen Yu; M Neal Guentzel; Hans W Heidner; Karl E Klose; Bernard P Arulanandam
Journal:  Vaccine       Date:  2014-07-19       Impact factor: 3.641

Review 4.  Adaptive Immunity to Francisella tularensis and Considerations for Vaccine Development.

Authors:  Lydia M Roberts; Daniel A Powell; Jeffrey A Frelinger
Journal:  Front Cell Infect Microbiol       Date:  2018-04-06       Impact factor: 5.293

5.  Tularemia vaccine development: paralysis or progress?

Authors:  Raju Sunagar; Sudeep Kumar; Brian J Franz; Edmund J Gosselin
Journal:  Vaccine (Auckl)       Date:  2016-05-04

Review 6.  Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.

Authors:  Qingmei Jia; Marcus A Horwitz
Journal:  Front Cell Infect Microbiol       Date:  2018-05-15       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.